Dapoxetine: In premature ejaculation

Drugs

Volumn 70, Issue 11, 2010, Pages 1433-1443

  Hoy, Sheridan M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Dapoxetine, general; Premature ejaculation

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CYTOCHROME P450 INHIBITOR; DAPOXETINE; DESIPRAMINE; DILTIAZEM; DRUG METABOLITE; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GLIBENCLAMIDE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MIDAZOLAM; MONOAMINE OXIDASE INHIBITOR; NORDAPOXETINE; OMEPRAZOLE; PHOSPHODIESTERASE INHIBITOR; PRILIGY; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TAMSULOSIN; TELITHROMYCIN; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN; BENZYLAMINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; INSOMNIA; LIBIDO DISORDER; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARAMETER; PLASMA CONCENTRATION-TIME CURVE; PREMATURE EJACULATION; REVIEW; RHINOPHARYNGITIS; SEIZURE; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SINUS ARREST; SINUS BRADYCARDIA; SOMNOLENCE; SYNCOPE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ADULT; COITUS; DRUG EFFECTS; EJACULATION; FEMALE; MALE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

ADULT; BENZYLAMINES; COITUS; EJACULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

EID: 77954556700     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204750-000000000-00000     Document Type: Review

References (46)

1. American Urological Association. Guideline on the phar-macological management of premature ejaculation [online]. Available from URL: http://www.auanet.org/content/guide lines-and-quality-care/clinical-guidelines/ main-reports/pme/pme-2004.pdf [Accessed 2009 Dec 1]
2. Giuliano F, Clement P. Serotonin and premature ejacula-tion: from physiology to patient management. Eur Urol 2006 Sep; 50 (3): 454-466
3. McMahon CG, Althof S, Waldinger MD, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 2008 Aug; 102 (3): 338-350 (Pubitemid 352019206)
4. Hellstrom WJ. Emerging treatments for premature ejacula-tion: focus on dapoxetine. Neuropsychiatr Dis Treat 2009; 5: 37-46
5. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010 Feb 20; 57 (5): 804-814
6. Ahlenius S, Larsson K, Svensson L, et al. Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav 1981 Nov; 15 (5): 785-792
7. Coolen LM, Olivier B, Peters HJ, et al. Demonstration of ejaculation-induced neural activity in the male rat brain using 5-HT1A agonist 8-OH-DPAT. Physiol Behav 1997 Oct; 62 (4): 881-891
8. Waldinger MD, Berendsen HH, Blok BF, et al. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998 May; 92 (2): 111-118
9. Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int 2008 Sep; 102 (6): 668-675
10. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002 Dec; 168 (6): 2359-2367
11. Olivier B, Chan JS, Pattij T, et al. Psychopharmacology of male rat sexual behavior: modeling human sexual dysfunctions? Int J Impot Res 2006 Sep 31; 18 Suppl. 1: S14-23
12. Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004 Aug; 16 (4): 369-381
13. Modi N, Dresser M, Wang B, et al. Dapoxetine pharmaco-kinetics and tolerability in hypertensive men [abstract no. 173]. Eur Urol Suppl 2006 Apr; 5 (2): 66
14. Modi NB, Nath R, Staehr P, et al. Pharmacokinetic, pharma-codynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. J Clin Pharmacol 2009 Jun; 49 (6): 634-642
15. Giuliano F, Bernabe J, Gengo P, et al. Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. J Urol 2007 Jan; 177 (1): 386-389
16. Clement P, Bernabe J, Gengo P, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxe-tine. Eur Urol 2007 Mar; 51 (3): 825-832
17. Janssen-Cilag (New Zealand) Ltd. Priligy® data sheet [on-line]. Available from URL: http://www.medsafe.govt.nz/Profs/Datasheet/p/Priligytab.pdf [Accessed 2010 May 21]
18. Medical Products Agency. Priligy: public assessment report [online]. Available from URL: http://www.lakemedelsverket. se/SPC-PIL/Pdf/par/ Priligy%20film%20coated%20tablets% 2030%20and%2060%20mg.pdf [Accessed 2010 Feb 22]
19. Thyssen A, Sharma O, Tianmei S, et al. Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men. J Clin Pharmacol. Epub 2010 Jan 23
20. Modi NB, Dresser MJ, Simon M, et al. Single-and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006 Mar; 46 (3): 301-309
21. Dresser MJ, Kang D, Staehr P, et al. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal. J Clin Pharmacol 2006 Sep; 46 (9): 1023-1029
22. Dresser MJ, Desai D, Gidwani S, et al. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 2006 Jan-Feb; 18 (1): 104-110
23. Modi NB, Kell S, Aquilina J, et al. Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsu-losin in men on a stable dose of tamsulosin. J Clin Pharmacol 2008 Dec; 48 (12): 1438-1450
24. Modi NB, Dresser M, Desai D, et al. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol 2007 Mar; 47 (3): 315-322
25. McMahon C, Kim SW, Park NC, et al. Treatment of pre-mature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010 Jan; 7 (1 Pt 1): 256-268
26. Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009 Apr; 55 (4): 957-968
27. Pryor JL, Althof SE, Steidle C, et al. Efficacy and toler-ability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006 Sep; 368 (9539): 929-937
28. Kaufman JM, Rosen RC, Mudumbi RV, et al. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2009 Mar; 103 (5): 651-658
29. McMahon C, Althof S, Kaufman J, et al. Efficacy and safety of dapoxetine for premature ejaculation: integrated analysis of 5 phase 3 trials [abstract no. PD-068]. J Sex Med 2009; 6 Suppl. 2: 69-70.
30. Plus oral presentation presented at the Joint Congress of the European and International Societies for Sexual Medicine; 2008 Dec 7-11; Brussels
31. Shabsigh R, Broderick GA, Miloslavsky M, et al. Dapoxetine has long-term efficacy in the treatment of premature ejaculation [abstract no. 918]. J Urol 2006 Apr; 175 (4 Suppl.): 297-298
32. Hellstrom WJ, Sharlip ID, Miloslavsky M. Efficacy of dapoxe-tine in men with self-rated very poor control over ejaculation [abstract no. 917]. J Urol 2006 Apr; 175 (4 Suppl.): 297
33. McVary KT, Rosen R, Ho K-F, et al. Effect of dapoxetine on intravaginal ejaculatory latency time in men with lifelong or acquired premature ejaculation [abstract no. 99]. J Sex Med 2006 Jan; 3 Suppl. 1:45.
34. Plus poster presented at the 2005 Fall Meeting of the Sexual Medicine Society of North America; 2005 Nov 17-20; New York
35. Johnson & Johnson Pharmaceutical Research and Develop-ment LLC. A study of the effectiveness and safety of dapoxetine in the treatment of men with premature ejaculation [Clinical Trials.gov identifier NCT00229073]. US National Institutes of Health ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/[Accessed 2010 Apr 19]
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association, 2000
37. Shabsigh R, Tesfaye F. Low incidence of sexual side effects with dapoxetine (DPX) for the treatment of premature ejaculation [abstract no. 78]. J Sex Med 2008; 5 Suppl. 1: 31.
38. Plus poster presented at the Winter Scientific Meeting of the Sexual Medicine Society of North America; 2007 Dec 6-9; Chicago (IL)
39. Levine SB, Casey RW, Mudumbi RV, et al. Evaluation of withdrawal effects with dapoxetine in the treatment of premature ejaculation (PE) [abstract no. 82]. J Sex Med 2007; 4 Suppl. 1: 91.
40. Plus poster presented at the Fall Meeting of the Sexual Medicine Society of North America; 2006 Nov 2-5; Las Vegas (NV)
41. Giuliano F, Levine SB, Buvat J, et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation: results from 2 phase III trials. Eur Urol Suppl 2008 Mar; 7 (3): 187.
42. Plus poster presented at the 23rd Annual Congress of the European Association of Urology; 2008 Mar 26-29; Milan
43. Shabsigh R, Broderick G, Miloslavsky M, et al. Long-term safety and tolerability of dapoxetine for the treatment of men with premature ejaculation [abstract no. 174]. Eur Urol Suppl 2006 Apr; 5 (2): 66.
44. Plus poster presented at the 2006 Annual Congress of the European Association of Urology; 2006 Apr 5-8; Paris
45. Janssen-Cilag EMEA. Priligy™ (dapoxetine) receives first regulatory approvals for the treatment of premature ejaculation (PE) in Finland and Sweden [online]. Available from URL: http://www.jnj.com/connect/news/all/20090210- 140000 [Accessed 2009 Dec 1]
46. PPD Inc. PPD confirms Johnson & Johnson Pharmaceutical Research & Development's completion of additional phase III studies providing expanded safety and efficacy data for Priligy® [online]. Available from URL: http://investor. ppdi.com/releasedetail.cfm?ReleaseID=388938 [Accessed 2010 Mar 26]